Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Predictive Value of aEEG and Cerebral Oxygenation on Neurological Outcomes in Newborns With Mild Hypoxic-Ischemic Encephalopathy

NCT07393620 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-02-10
Last updated
2026-05-01

Condition(s) studied

Hypoxic-Ischemic Encephalopathy Mild

Study summary

Newborns with mild hypoxic-ischemic encephalopathy usually do not receive cooling treatment. However, some of these newborns may develop neurological problems later in life. This observational study aims to evaluate whether early brain monitoring and measurements of brain oxygen levels are associated with neurological outcomes in newborns with mild hypoxic-ischemic encephalopathy. Newborns will be monitored during the first 72 hours after birth as part of routine clinical care. Neurological assessments will be performed during early infancy and later follow-up. The findings of this study may help improve early risk assessment and support closer monitoring of newborns who may be at increased risk for unfavorable neurological outcomes.

Eligibility

Sex
ALL
Min age
0 Hours
Max age
6 Hours
Healthy volunteers
No
Inclusion Criteria: 1. Gestational age and postnatal age: Gestational age ≥ 36 0/7 weeks and enrollment within the first 6 hours after birth. 2. Blood gas criteria Umbilical cord or postnatal (≤ 1 hour of life) blood gas showing: 1. pH ≤ 7.00 or base deficit ≥ 16 mmol/L 2. OR, if pH is 7.01-7.15 or base deficit is 10-15.9 mmol/L, the presence of both: * An acute perinatal event, and * Apgar score ≤ 5 at 10 minutes or ongoing resuscitation at 10 minutes of life, including the need for positive pressure ventilation. ( Evidence of an acute peripartum and intrapartum asphyxia event, defined by at least one of the following: Uterine rupture, placental abruption, umbilical cord prolapse, rupture, tight nuchal cord, maternal hemorrhage, trauma, or cardiopulmonary arrest, vasa previa, category III fetal heart rate tracing, including having either a sinusoidal pattern or absent baseline variability plus recurrent late decelerations, recurrent variable decelerations, or bradycardia.) 3. Clinical evidence of encephalopathy Findings consistent with Sarnat and Sarnat Stage 1 (mild) encephalopathy. Mild, moderate, or severe abnormalities may be present in at least one of the six categories (level of consciousness, spontaneous activity, posture, tone, primitive reflexes \[suck and Moro\], autonomic nervous system), provided that no more than two categories show moderate or severe findings. Exclusion Criteria: Newborns meeting any of the following criteria will be excluded from the study: 1. Normal neurological examination Newborns with a completely normal neurological examination according to Sarnat and Sarnat staging. 2. Moderate or severe encephalopathy within the first 6 hours of life 1. Clinical findings consistent with moderate or severe encephalopathy during the first 6 hours after birth. 2. Presence of clinical seizures. 3. aEEG findings consistent with moderate or severe encephalopathy requiring therapeutic hypothermia. 4. Evidence of electrographic seizure activity on aEEG monitoring. 3. Sarnat and Sarnat criteria for moderate-severe encephalopathy Findings consistent with moderate or severe encephalopathy in three or more Sarnat categories, classified as moderate or severe hypoxic-ischemic encephalopathy. 4. Contraindications to therapeutic hypothermia, including: * Evaluation occurring more than 6 hours after birth. * Gestational age \< 36 weeks or birth weight \< 2000 g. * Severe or extensive intracranial parenchymal hemorrhage. * Severe, life-threatening coagulopathy. * Intracerebral infarction. * Chromosomal abnormalities (e.g., trisomy 13 or 18) or major congenital anomalies involving multiple organ systems. 5. Lack of parental informed consent 6. Cyanotic congenital heart disease 7. Metabolic encephalopathy Encephalopathy due to metabolic disorders not related to hypoxic-ischemic events. 8. Other conditions associated with encephalopathy unrelated to acute hypoxia * Abnormal fetal growth. * Maternal infections. * Fetomaternal hemorrhage. * Severe neonatal sepsis. * Chronic placental lesions.

Primary outcome measure(s)

  • Neurological Outcomes in Neonates with Mild Hypoxic-ischemic Encephalopathy — at 18 and 24 months of age
    The primary outcome measure is the report of neurological outcome in children diagnosed with mild hypoxic-ischemic encephalopathy. Neurological outcome will be measured using the Bayley Scales of Infant and Toddler Development (Bayley-III) at 18-24 months of age; a standard score below 85 in at least one of the cognitive, motor, or language domains will be defined as a neurologic disorder.

Trial sites (3)

FacilityCityRegionStatus
Bursa City Hospital Bursa Turkey (Türkiye) Recruiting
Division of Neonatology, Department of Pediatrics, Bursa Uludağ University Faculty of Medicine Bursa Turkey (Türkiye) Recruiting
Division of Neonatology, Department of Pediatrics, University of Health Sciences Bursa Yuksek İhtisas Training and Research Hospital Bursa Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07393620 on ClinicalTrials.gov ↗ ← All trials in Turkey